The table below shows Xeris Biopharma Holdings, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$9.87M
-$10.03M
-$20.30M
-$26.14M
-$48.41M
-$23.96M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
-$325.00K
-$13.00K
-$19.65M
-$43.98M
$6.72M
$26.30M
Dividends paid
-
-
-
-
XERS operating cash flow (10-K history)
Xeris Biopharma Holdings, Inc. reported operating cash flow of $28.63M for fiscal year 2025. That is up 177.4% from -$36.98M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$80.56M (FY 2020) to $28.63M. Figures come from the company's audited annual reports as filed with the SEC.